These findings suggest a local treatment strategy for cholesteatoma by specifically targeting TLR4-mediated pro-inflammatory down-stream signaling in cholesteatoma stem cells as mediators of inflammation and cholesteatoma progression (Figure 7). The gene discussed is TLR4; the disease is cholesteatoma.